Inge Svane-Marie

Herlev, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Art of TIL immunotherapy: SITC's perspective on demystifying a complex treatment.

Art of TIL immunotherapy: SITC's perspective on demystifying a complex treatment.

Journal: Journal for immunotherapy of cancer

Published: December 03, 2024

Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020.

Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020.

Journal: Journal for immunotherapy of cancer

Published: December 02, 2024

Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma.

Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma.

Journal: Journal for immunotherapy of cancer

Published: May 01, 2024

Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial.

Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial.

Journal: Journal for immunotherapy of cancer

Published: February 26, 2024

Intratumoral T-cell and B-cell receptor architecture associates with distinct immune tumor microenvironment features and clinical outcomes of anti-PD-1/L1 immunotherapy.

Intratumoral T-cell and B-cell receptor architecture associates with distinct immune tumor microenvironment features and clinical outcomes of anti-PD-1/L1 immunotherapy.

Journal: Journal for immunotherapy of cancer

Published: July 17, 2023

TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapy.

TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapy.

Journal: Journal for immunotherapy of cancer

Published: July 16, 2023

Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy.

Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy.

Journal: Journal for immunotherapy of cancer

Published: February 27, 2023

Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells.

Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells.

Journal: Journal for immunotherapy of cancer

Published: September 22, 2022

COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis.

COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis.

Journal: Journal for immunotherapy of cancer

Published: July 11, 2022

Showing 1-9 of 9

Last Updated: 09/26/2026